Metabolic tumor volume and total lesion glycolysis for predicting prognosis in diffuse large B-cell lymphoma: a retrospective PET/CT study
Baseline ^18F-FDG PET/CT-derived volumetric metabolic parameters in newly diagnosed DLBCL.
BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is characterized by marked clinical heterogeneity, and conventional prognostic indices provide limited individualized risk prediction. We investigated the prognostic value of baseline ^18F-FDG PET/CT-derived volumetric metabolic parameters in newly diagnosed DLBCL.
It establishes the study’s focus on evaluating pre-treatment PET/CT metabolic metrics as potential prognostic biomarkers in DLBCL, the most common aggressive lymphoma subtype.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Diffuse Large B‑Cell Lymphoma – Global Clinical Trial Landscape (2024)
- Mantle‑Cell Lymphoma (MCL)
- Inhibition of autoantigen‑induced B‑cell receptor (BCR) internalization as a therapeutic strategy in diffuse large B cell lymphoma (DLBCL)
- Successful treatment of primary refractory DLBCL/HGBL - MYC/BCL2 transformed from FL using glofitamab: a case report
- Loncastuximab in high‑risk and heavily pre‑treated relapsed/refractory diffuse large B‑cell lymphoma: a real‑world analysis from 21 US centers